Epilepsy - Pipeline Review, Q1 2011
Global Markets Direct, February 2011, Pages: 85
Epilepsy - Pipeline Review, Q1 2011
Summary
Global Markets Direct’s, 'Epilepsy - Pipeline Review, Q1 2011', provides an overview of the Epilepsy therapeutic pipeline. This report provides information on the therapeutic development for Epilepsy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Epilepsy. 'Epilepsy - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Epilepsy.
- A review of the Epilepsy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Epilepsy pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Epilepsy.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Epilepsy pipeline depth and focus of Epilepsy therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
List of Tables
List of Figures
Introduction
Epilepsy Overview
Therapeutics Development
Epilepsy Therapeutics under Development by Companies
Epilepsy Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Mid Clinical Stage Products
Early Clinical Stage Products
Discovery and Pre-Clinical Stage Products
Companies Involved in Epilepsy Therapeutics Development
Universities/Institutes Involved in Epilepsy Therapeutics Development
Epilepsy - Therapeutics Assessment
Late Stage Drug Profiles – Companies
Late Stage Drug Profiles – Universities/Institutes
Discontinued Products
Appendix
Methodology
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Epilepsy, 2011
Products under Development for Epilepsy – Comparative Analysis, 2011
Comparative Analysis by Late Stage Development, 2011
Comparative Analysis by Mid Clinical Stage Development, 2011
Comparative Analysis by Early Clinical Stage Development, 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, 2011
Johnson & Johnson, 2011
NsGene A/S, 2011
Neurocrine Biosciences, Inc., 2011
Archimedes Pharma Limited, 2011
Novartis AG, 2011
Eisai Co., Ltd., 2011
H Lundbeck A/S, 2011
King Pharmaceuticals, Inc., 2011
Pfizer Inc., 2011
UCB Group, 2011
Vertex Pharmaceuticals Incorporated, 2011
Sun Pharmaceutical Industries Limited, 2011
Aeolus Pharmaceuticals, Inc., 2011
GW Pharmaceuticals plc, 2011
Icagen Inc, 2011
Anavex Life Sciences Corp., 2011
Amarin Corporation plc, 2011
Bionomics Limited, 2011
Neurologix, Inc., 2011
Catalyst Pharmaceutical Partners, Inc., 2011
NPS Pharmaceuticals, Inc., 2011
Jazz Pharmaceuticals, Inc., 2011
Proximagen Neuroscience plc., 2011
Paloma Pharmaceuticals, Inc., 2011
Bio-Link, 2011
D-Pharm Ltd., 2011
VistaGen Therapeutics , Inc., 2011
Upsher-Smith Laboratories, Inc., 2011
Snowdon Inc., 2011
BioMAS Ltd., 2011
BioQuest Innovations Inc., 2011
Supernus Pharmaceuticals, Inc., 2011
Nobelpharma Co., Ltd., 2011
CyDex Pharmaceuticals, Inc., 2011
Concert Pharmaceuticals, Inc., 2011
Bial Group, 2011
Biovista Inc., 2011
Marinus Pharmaceuticals, Inc., 2011
Desitin Arzneimittel GMBH, 2011
SK Bio-Pharmaceuticals, 2011
Assessment by Monotherapy Products, 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Discontinued Products
List of Figures
Number of Products under Development for Epilepsy, 2011
Products under Development for Epilepsy – Comparative Analysis, 2011
Products under Development by Companies, 2011
Products under Investigation by Universities/Institutes, 2011
Late Stage Products, 2011
Mid Clinical Stage Products, 2011
Early Clinical Stage Products, 2011
Discovery and Pre-Clinical Stage Products, 2011
Assessment by Monotherapy Products, 2011
Assessment by Combination Products, 2011
Assessment by Route of Administration, 2011
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Assessment by Stage and Molecule Type, 2011
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
